Clinical Observation Of Treatment On Advanced Lung Adenocarcinoma With Endostar Deliveried By Different Ways And Chemotherapy

Objective: To observe the clinical efficacy and adverse reactions of Pemetrexed,endostatin,with cisplatin chemotherapy in the two different modes of administration of advanced lung adenocarcinoma.Methods: Data of 48 patients diagnosed with IIIB / IV stage lung adenocarcinoma were collected from December 2014-December 2016 in our hospital and these patients were randomly assigned to experimental group and control group with random number table methodin which 26 patients were included in experimental group while the rest 22 patients were involved in control group..These patients were all treated with Endu combined with pemetrexed cisplatin + cisplatin regimen.The experimental group was treated with intravenous pump,and the control group was infused daily.The relevant biological and clinical characteristics of the two groups patients were collected.The results of the treatment before and after the first treatment were recorded,including CR,PR,adverse reactions.Relevant indicators were calculated and assessed with statistical methods analysis.Result: 1.The rate(CR + PR)obtained after the second cycle,4th cycle and 6th cycle were compared respectively in experimental group and control group and there was no significant difference between the two groups(p > 0.05).The control rate(CR +PR + SD)in experimental group and control group after the second cycle was 80.8%and 72.7%,which has no significantly difference(p> 0.05).The rate after fourth period in experimental group was significantly higher than those in control group(p<0.05),which was 78.9 and 42.9%,respectively.The rate after sixth cycle was 58.3%in experimental group and 50.0% in control group,which the difference in two group rate was not statistically significant.2.The major chemotherapy side effects in two groups of patients were level I ~ II,the level of ? ~ ? ° adversereactions are mainly concentrated in hematology and gastrointestinal toxicity,and the incidence rate is low.There were no significant differences in the adverse reactions between the two group(p > 0.05).3.The median survival time(m PFS)is 7.2 months in the experimental group 6.6months in control group,which the difference in rate was statistically significant.Conclusion:1.Along the early stage of increase in number of chemotherapy cycles,continuous Endostar micro-infusion pump to fourth cycle can improve the control rate of advanced lung adenocarcinoma disease in compared with the intermittent intravenous infusion.However,the improvement would disappear when the treatment continue to sixth cycle.2.In compared with the traditional 14-day intermittent intravenous infusion,continuous micro-infusion pump will not increase the degree of toxic side effects of treatment on advanced lung adenocarcinoma disease with endostain and chemotherapy,which is suggestive that this treatment is relatively safe in clinical practice.3.In compared with the intermittent intravenous infusion,Continuous micro-infusion pump therapy can prolong the median progression-free survival time(m PFS)in advanced lung adenocarcinoma disease,which means this therapy is worth promoting.